XTL Biopharmaceuticals Sponsored ADR(XTLB)
$1.66-0.05 (-2.64%)
XTLB
XTL Biopharmaceuticals Sponsored ADR financials statements
$1.66
At close:-0.05 (-2.64%)
Want to see XTLB full AI Analyst Report?
XTL Biopharmaceuticals Sponsored ADR (XTLB) Ratios
148 Followers
XTL Biopharmaceuticals Sponsored ADR Ratios
XTLB's free cash flow for Q4 2024 was $0.00. For the 2024 fiscal year, XTLB's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.40 | 0.61 | 9.93 | 20.35 | 27.00 |
| Quick Ratio | 0.40 | 0.61 | 9.93 | 20.35 | 27.00 |
| Cash Ratio | 0.18 | 0.17 | 6.80 | 11.20 | 12.85 |
| Solvency Ratio | -16.59 | -0.27 | -0.00 | -7.20 | 0.34 |
| Operating Cash Flow Ratio | -2.44 | -0.73 | -3.43 | -4.82 | -4.54 |
| Short-Term Operating Cash Flow Coverage | -3.81 | -11.72 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -254.00K | $ -1.77M | $ 1.84M | $ 3.62M | $ 4.95M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.62 | 0.02 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | -1.06 | 0.03 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 17.93 | 0.02 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.65 | 1.57 | 1.09 | 1.05 | 1.24 |
| Debt Service Coverage Ratio | -2.72 | -3.57 | -191.05 | -79.92 | -49.05 |
| Interest Coverage Ratio | -241.14 | -25.26 | -191.30 | -80.01 | -49.10 |
| Debt to Market Cap | 0.28 | 0.16 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.66 | 2.13 | 0.00 | 0.01 | 0.02 |
| Net Debt to EBITDA | -0.26 | 0.25 | 1.83 | 2.38 | 2.88 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.67% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | -250.33% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | -206.21% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | -481.60% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | -256.54% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | -227.72% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | -227.72% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 918.18% | 88.76% | 0.10% | 100.00% | 100.00% |
| EBT Per EBIT | 44.96% | 53.27% | 232.94% | 153.18% | -42.19% |
| Return on Assets (ROA) | -4198.19% | -12.01% | -0.07% | -32.20% | 6.57% |
| Return on Equity (ROE) | 2743.70% | -18.90% | -0.08% | -33.71% | 8.16% |
| Return on Capital Employed (ROCE) | 664.57% | -34.24% | -34.46% | -22.01% | -16.14% |
| Return on Invested Capital (ROIC) | -11253.33% | -29.75% | -34.46% | -22.01% | -16.14% |
| Return on Tangible Assets | -4198.19% | -66.65% | -0.09% | -35.42% | 6.97% |
| Earnings Yield | -714.10% | -120.27% | -0.13% | -81.75% | 11.81% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 4.56 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 2.29 | 0.00 | 0.50 | 0.50 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 2.41 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.93 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -79.57 | 0.00 | -730.00 | -730.00 |
| Days of Sales Outstanding | 0.00 | 80.12 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 159.69 | 0.00 | 730.00 | 730.00 |
| Operating Cycle | 0.00 | 80.12 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.44 | -15.39 | -0.52 | -0.66 | -0.79 |
| Free Cash Flow Per Share | -2.44 | -15.90 | -0.52 | -0.66 | -0.79 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -29.96 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | -29.96 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -3.81 | -11.72 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | -3.59 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -105.03% | -195.80% | -51.38% | -54.64% | -28.47% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.14 | -0.85 | -772.17 | -1.22 | 8.47 |
| Price-to-Sales (P/S) Ratio | 0.00 | 1.89 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -3.84 | 0.16 | 0.62 | 0.41 | 0.69 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.95 | -0.51 | -1.95 | -1.83 | -3.51 |
| Price-to-Operating Cash Flow Ratio | -0.95 | -0.53 | -1.95 | -1.83 | -3.51 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.01 | 7.72 | 0.00 | -0.07 |
| Enterprise Value Multiple | -1.55 | -0.67 | 0.03 | 0.51 | -0.69 |
| Enterprise Value | 1.17M | 620.92K | -24.99K | -445.11K | 715.07K |
| EV to EBITDA | -1.55 | -0.67 | 0.03 | 0.51 | -0.69 |
| EV to Sales | 0.00 | 1.38 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -1.14 | -0.37 | 0.04 | 0.49 | -0.68 |
| EV to Operating Cash Flow | -1.14 | -0.38 | 0.04 | 0.49 | -0.68 |
| Tangible Book Value Per Share | -0.60 | -14.97 | 1.35 | 2.66 | 3.72 |
| Shareholders’ Equity Per Share | -0.60 | 51.68 | 1.63 | 2.93 | 4.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.11 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 4.29 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -16.57 | -9.77 | -0.00 | -0.99 | 0.33 |
| Tax Burden | 9.18 | 0.89 | 0.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.02 | 2.33 | 1.53 | -0.42 |
| Research & Development to Revenue | 0.00 | 0.22 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 4.54 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.59 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.15 | 1.58 | 0.40 | 0.67 | -2.41 |
Currency in USD
